IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.46%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$257M
AUM Growth
-$6.27M
Cap. Flow
-$29.2M
Cap. Flow %
-11.36%
Top 10 Hldgs %
53.62%
Holding
74
New
14
Increased
16
Reduced
17
Closed
18
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$3.75M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.53M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.48M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$3.35M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.35M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.04M
2
VTRS icon
Viatris
VTRS
+$5.43M
3
SHPG
Shire pic
SHPG
+$5.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.01M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$26.3M 10.24%
180,522
+3,000
+2% +$409K
2016 Q4
3 quarters
BIIB icon
2
Biogen
BIIB
$34.4B
$22.4M 8.71%
71,508
+10,400
+17% +$3.08M
2016 Q4
3 quarters
REGN icon
3
Regeneron Pharmaceuticals
REGN
$80.1B
$18.3M 7.11%
40,830
-7,300
-15% -$3.47M
2016 Q4
3 quarters
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$126B
$13.5M 5.25%
88,722
-46,800
-35% -$7.04M
2016 Q4
3 quarters
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$12.9M 5.03%
92,141
-4,500
-5% -$611K
2016 Q4
3 quarters
INCY icon
6
Incyte
INCY
$22.6B
$10.4M 4.04%
88,975
+11,500
+15% +$1.45M
2016 Q4
3 quarters
GILD icon
7
Gilead Sciences
GILD
$190B
$9.95M 3.87%
122,784
+1,000
+0.8% +$76.5K
2016 Q4
3 quarters
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$3.32B
$9.07M 3.53%
240,773
+103,000
+75% +$3.35M
2016 Q4
3 quarters
ADMS
9
DELISTED
Adamas Pharmaceuticals
ADMS
$8.25M 3.21%
390,000
+204,766
+111% +$3.75M
2016 Q4
3 quarters
AMGN icon
10
Amgen
AMGN
$230B
$6.73M 2.62%
36,104
-14,000
-28% -$2.48M
2016 Q4
3 quarters
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$10.7B
$6.36M 2.48%
68,384
-49,782
-42% -$4.4M
2016 Q4
3 quarters
ENTL icon
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$6.3M 2.45%
341,468
– –
2016 Q4
3 quarters
EXEL icon
13
Exelixis
EXEL
$15.1B
$6.16M 2.4%
254,334
+47,334
+23% +$1.26M
2016 Q4
3 quarters
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$5.75M 2.24%
153,633
-24,010
-14% -$833K
2016 Q4
3 quarters
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.78B
$5.49M 2.14%
121,000
+60,000
+98% +$2.4M
2017 Q2
1 quarter
PRTK
16
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.07M 1.97%
202,000
+144,000
+248% +$3.35M
2017 Q2
1 quarter
HALO icon
17
Halozyme
HALO
$13.3B
$4.91M 1.91%
282,633
+78,000
+38% +$1.06M
2016 Q4
3 quarters
ALNY icon
18
Alnylam Pharmaceuticals
ALNY
$30B
$4.85M 1.89%
+41,300
New +$3.53M
2017 Q3
0 quarters
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$4.61M 1.8%
56,000
+21,000
+60% +$1.66M
2016 Q4
3 quarters
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$4.52M 1.76%
35,000
+1,500
+4% +$186K
2016 Q4
3 quarters
SGMO icon
21
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.09M 1.59%
+273,000
New +$3.02M
2017 Q3
0 quarters
NBIX icon
22
Neurocrine Biosciences
NBIX
$13.8B
$4.04M 1.57%
+66,000
New +$3.48M
2017 Q3
0 quarters
LGND icon
23
Ligand Pharmaceuticals
LGND
$5.88B
$3.95M 1.54%
46,487
+32,060
+222% +$2.54M
2016 Q4
3 quarters
FPRX
24
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.54M 1.38%
86,500
+45,500
+111% +$1.43M
2017 Q2
1 quarter
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
$3.13M 1.22%
57,500
-7,500
-12% -$384K
2017 Q1
2 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2017 Portfolio in Review

As of Q3 2017, International Biotechnology Trust held 74 positions worth $257M, down 2.4% from $263M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust withdrew a net $29.2M in Q3 2017, closing 18 positions and reducing 17 holdings. Its most notable exit was Viatris, an estimated $5.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Alnylam Pharmaceuticals worth $4.85M.

  • International Biotechnology Trust's largest Q3 2017 buy was Alnylam Pharmaceuticals: 41,300 shares worth $4.85M.
  • International Biotechnology Trust added most to Adamas Pharmaceuticals in Q3 2017, an estimated $3.75M increase.
  • International Biotechnology Trust's biggest Q3 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $7.04M.
  • International Biotechnology Trust fully exited Viatris in Q3 2017, selling an estimated $5.43M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $257M portfolio in Q3 2017.
  • International Biotechnology Trust opened 14 new positions and closed 18 in Q3 2017.
  • International Biotechnology Trust's portfolio value fell 2.4% quarter-over-quarter to $257M.

Based on International Biotechnology Trust's 13F filing for Q3 2017, filed 2 Mar 2018.